Literature DB >> 35482192

A Hybrid Adherent/Suspension Cell-Based Selection Strategy for Discovery of Antibodies Targeting Membrane Proteins.

Patrick J Krohl1, Jamie B Spangler2,3,4,5,6,7,8.   

Abstract

Membrane proteins are favored drug targets and antibody therapeutics represent the fastest-growing category of pharmaceuticals. However, there remains a need for rapid and effective approaches for the discovery of antibodies that recognize membrane proteins to develop a robust clinical pipeline for targeted therapeutics. The challenges associated with recombinant expression of membrane proteins make whole cell screening techniques desirable, as these strategies allow presentation of the target membrane proteins in their native conformations. Here, we describe a workflow that employs both adherent cell-based and suspension cell-based whole cell panning methodologies to enrich for specific binders within a yeast-displayed antibody library. The first round of selection consists of an adherent cell-based approach, wherein a diverse library is panned over target-expressing mammalian cell monolayers in order to debulk the naïve library. Subsequent rounds involve the use of suspension cell-based approaches, facilitated with magnetic-activated cell sorting (MACS) or fluorescence-activated cell sorting (FACS), to achieve further library enrichment. Finally, we describe a high-throughput approach to screen target binding and specificity of individual clones isolated from selection campaigns.
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Antibody discovery; Biopanning; Cell panning; Directed evolution; Membrane proteins; Molecular engineering; Yeast surface display

Mesh:

Substances:

Year:  2022        PMID: 35482192     DOI: 10.1007/978-1-0716-2285-8_11

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  15 in total

Review 1.  Clinical pharmacokinetics of therapeutic monoclonal antibodies.

Authors:  Ron J Keizer; Alwin D R Huitema; Jan H M Schellens; Jos H Beijnen
Journal:  Clin Pharmacokinet       Date:  2010-08       Impact factor: 6.447

Review 2.  Therapeutic antibodies directed at G protein-coupled receptors.

Authors:  Catherine J Hutchings; Markus Koglin; Fiona H Marshall
Journal:  MAbs       Date:  2010-11-01       Impact factor: 5.857

3.  Searching for peptide ligands with an epitope library.

Authors:  J K Scott; G P Smith
Journal:  Science       Date:  1990-07-27       Impact factor: 47.728

4.  Yeast surface display for screening combinatorial polypeptide libraries.

Authors:  E T Boder; K D Wittrup
Journal:  Nat Biotechnol       Date:  1997-06       Impact factor: 54.908

5.  Top companies and drugs by sales in 2019.

Authors:  Lisa Urquhart
Journal:  Nat Rev Drug Discov       Date:  2020-03-13       Impact factor: 84.694

Review 6.  Recent advances in nanodisc technology for membrane protein studies (2012-2017).

Authors:  John E Rouck; John E Krapf; Jahnabi Roy; Hannah C Huff; Aditi Das
Journal:  FEBS Lett       Date:  2017-07-06       Impact factor: 4.124

7.  Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display library.

Authors:  Michael J Feldhaus; Robert W Siegel; Lee K Opresko; James R Coleman; Jane M Weaver Feldhaus; Yik A Yeung; Jennifer R Cochran; Peter Heinzelman; David Colby; Jeffrey Swers; Christilyn Graff; H Steven Wiley; K Dane Wittrup
Journal:  Nat Biotechnol       Date:  2003-01-21       Impact factor: 54.908

8.  Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface.

Authors:  G P Smith
Journal:  Science       Date:  1985-06-14       Impact factor: 47.728

Review 9.  Drugging Membrane Protein Interactions.

Authors:  Hang Yin; Aaron D Flynn
Journal:  Annu Rev Biomed Eng       Date:  2016-02-05       Impact factor: 9.590

Review 10.  Development of therapeutic antibodies for the treatment of diseases.

Authors:  Ruei-Min Lu; Yu-Chyi Hwang; I-Ju Liu; Chi-Chiu Lee; Han-Zen Tsai; Hsin-Jung Li; Han-Chung Wu
Journal:  J Biomed Sci       Date:  2020-01-02       Impact factor: 8.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.